Sidley Represents RA Capital Management in Artios Pharma’s US$115 million Series D Funding

Sidley represented RA Capital Management as co-lead investor in relation to Artios Pharma Limited’s (Artois) US$115 million Series D financing. Artios is a biopharmaceutical company developing next-generation approaches in the DNA damage response (DDR) field ttrough its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers.

The company’s clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Polθ) inhibitor ART6043, as well as its pre-clinical programs, including DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cell’s remaining survival mechanisms. Artios’ mission is to develop new classes of medicines that exploit DDR pathways with the aim of improving outcomes for patients with hard-to-treat cancers.

The Sidley team was led by Private Equity partner Robert Darwin (London), supported by Ying Liu, managing associate (London); and Nicolas Gomez Ospina, associate (London).